Low-Molecular-Weight Mk2 Inhibitors: A Tough Nut to Crack!

• Lee JC , LaydonJT, McDonnellPCet al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994).
   PubMed Web of Science ®Google Scholar
• Han J , LeeJD, BibbsI, UlevitchRJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.Science265, 808–811 (1994).
   PubMed Web of Science ®Google Scholar
• Saklatvala J . The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.Curr. Opin. Pharmacol.4, 372–377 (2004).
   PubMed Web of Science ®Google Scholar
• Freshney NM , RawlinsonL, GuesdonFet al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039–1049 (1994).
   PubMed Web of Science ®Google Scholar
• Rouse J , CohenP, TrigonSet al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78, 1027–1037 (1994).
   PubMed Web of Science ®Google Scholar
• Duraisamy S , BajpaiM, BughaniU, DastidarSG, RayA, ChopraP. MK2: a novel molecular target for anti-inflammatory therapy.Expert Opin. Ther. Targets12, 921–936 (2008).
   PubMed Web of Science ®Google Scholar
• Ronkina N , KotlyarovA, GaestelM. MK2 and MK3 – a pair of isoenzymes?Frontiers Biosci.13, 5511–5521 (2008).
   PubMed Web of Science ®Google Scholar
• Huang CK , ZhanI, AiY, JongstraJ. LSP-1 is the major substrate for mitogen-activated protein kinase-activated protein kinase 2 in human neutrophils.J. Biol. Chem.272, 17–29 (1997).
   PubMedGoogle Scholar
• Kotlyarov A , NeiningerA, SchubertCet al. MAPKAP kinase 2 is essential for LPS-induced TNFα biosynthesis. Nat. Cell. Biol. 1, 94–97 (1999).
   PubMed Web of Science ®Google Scholar
• Hegen M , GaestelM, Nickerson-NutterCL, Lin L-L, Telliez J-B. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J. Immunol.177, 1913–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Gorska MM , LiangQ, StaffordSJet al. MK2 controls the level of negative feedback in the NF-κB pathway and is essential for vascular permeability and airway inflammation. J. Exp. Med. 204, 1637–1652 (2007).
   PubMed Web of Science ®Google Scholar
• Funding AT , JohansenC, GaestelMet al. Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. J. Invest. Dermatol. 129, 891–898 (2009).
   PubMed Web of Science ®Google Scholar
• Tietz AB , MaloA, DieboldJ, GaestelM, GoekeB, SchaeferC. Gene deletion of MK2 inhibits TNF-α and IL-6 and protects against cerulein-induced pancreatitis.Am. J. Physiol. Gastroint. Liver Physiol.290, 1298–1306 (2006).
   Web of Science ®Google Scholar
• Jagavelu K , TietgeUJ, GaestelM, DrexlerH, SchiefferB, BavendiekU. Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice.Circ. Res.101, 1104–1112 (2007).
   PubMed Web of Science ®Google Scholar
• Nagy N , ShirotoG, MalikCKet al. Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J. Mol. Cell Cardiol. 42, 981–990 (2007).
   PubMed Web of Science ®Google Scholar
• Wang X , XuL, WangP, YoungR, GaestelM, FeuersteinGZ. Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice.J. Biol. Chem.277, 43968–43972 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas T , TimmerM, CesnuleviciusK, HittiE, KotlyarovA, GaestelM. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation – relevance in a mouse model of Parkinson’s disease.J. Neurochem.105, 2039–2052 (2008).
   PubMed Web of Science ®Google Scholar
• Culbert AA , SkaperSD, HowlettDRet al. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. J. Biol. Chem. 281, 23658–23667 (2006).
   PubMed Web of Science ®Google Scholar
• Kotlyarov A , YannoniY, FritzSet al. Distinct cellular functions of MK2. Mol. Cell. Biol. 22, 4827–4835 (2002).
   PubMed Web of Science ®Google Scholar
• Johansen C , ToftegaardAF, OtkjaerCet al. Protein expression of TNF-α in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J. Immunol. 176, 1431–1438 (2006).
   PubMed Web of Science ®Google Scholar
• Miyazawa K , MoriA, MiyataH, AkahaneM, AjisawaY, OkudairaH. Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase.J. Biol. Chem.273, 24832–24838 (1998).
   PubMed Web of Science ®Google Scholar
• Schett G , ZwerinaJ, FiresteinG. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.Ann. Rheum. Diss.67, 909–916 (2008).
   PubMed Web of Science ®Google Scholar
• Ronkina N , KotlyarovA, Dittrich-BreiholzOet al. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 27, 170–181 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson DR , HegdeS, ReinhardEet al. Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2). Bioorg. Med. Chem. Lett. 15, 1587–1590 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson DR , MeyersMJ, VernierWFet al. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein Kinase 2 (MK-2). J. Med. Chem. 50, 2647–2654 (2007).
   PubMed Web of Science ®Google Scholar
• Hillig CH , EberspaecherU, MonteclaroFet al. Structural basis for high affinity inhibitor bound to protein kinase MK2. J. Mol. Biol. 369, 735–745 (2007).
   PubMed Web of Science ®Google Scholar
• Schlapbach A , FeifelR, HawtinSet al. Pyrrolopyrimidones: a novel class of MK2 inhibitors with potent cellular activity. Bioorg. Med. Chem. Lett. 18, 6142–6146 (2008).
   PubMed Web of Science ®Google Scholar
• Trujillo JI , MeyersMJ, AndersonDRet al. Novel tetrahydro-β-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase (MK-2). Bioorg. Med. Chem. Lett. 17, 4657–4663 (2007).
   PubMed Web of Science ®Google Scholar
• Wu J -P, Wang J, Abeywardane A et al. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors. Bioorg. Med. Chem. Lett.17, 4664–4669 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg DR , ChoiY, CoganDet al. Pyrazinoindolone inhibitors of MAPKAP-K2. Bioorg. Med. Chem. Lett. 18, 938–941 (2008).
   PubMed Web of Science ®Google Scholar
• Xiong Z , GaoDA, CoganDAet al. Synthesis and SAR studies of indole-based MK2 inhibitors. Bioorg. Med. Chem. Lett. 18, 1994–1999 (2008).
   PubMedGoogle Scholar
• Lovering F , KirincichS, WangWet al. Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg. Med. Chem. 17, 3342–3351 (2009).
   PubMed Web of Science ®Google Scholar
• Dumitru CD , CeciJD, TsatsanisCet al. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103, 1071–1083 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen P . Targeting protein kinases for the development of anti-inflammatory drugs.Curr. Op. Cell Biol.21, 317–324 (2009).
   PubMed Web of Science ®Google Scholar
• Lord KA , CreasyAGK, KingC, BurnsBM, LeeJC, DillonSB. REDK, a novel human regulatory erythroid kinase.Blood95, 2838–2846 (2000).
   PubMed Web of Science ®Google Scholar
• Constantine KL , MuellerL, MetzlerWJet al. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear Overhauser effects. J. Med. Chem. 51, 6225–6229 (2008).
   PubMed Web of Science ®Google Scholar
• Jahnke J . Fragment-based approaches. In: Comprehensive Medicinal Chemistry II (Volume 3). Taylor JB, Tiggle DJ (Eds). Elsevier Ltd, Oxford, UK, 939–957 (2006).
   Google Scholar
• Davies SP , ReddyH, CaivanoM, CohenP. Specificity and mechanism of action of some commonly used protein kinase inhibitors.Biochem. J.351, 95–105 (2000).
   PubMed Web of Science ®Google Scholar
• Gschwendt M , MullerHJ, KielbassaKet al. Rottlerin: a novel protein kinase inhibitor. Biochem. Biophys. Res. Commun. 199, 93–98 (1994).
   PubMed Web of Science ®Google Scholar
• Soltoff SP : Rottlerin: an inappropriate and ineffective inhibitor of PKCd.Trends Pharmacol. Sci.28, 453–458 (2007).
   PubMed Web of Science ®Google Scholar
• Williams DE , Telliez J-B, Liu J, Tahir A, van Soest R, Andersen RJ. Meroterpenoid MAPKAP (MK2) inhibitors isolated from the Indonesian marine sponge Acathodendrilla sp. J. Nat. Prod.67, 2127–2129 (2004).
   PubMed Web of Science ®Google Scholar
• Graziani EI , RitaccoFV, BernanVS, Telliez J-B. Phaeeochromycins A-E: anti-inflammatory polyketides isolated from the soil actinomycete Streptomyces phaeochromogenes LL-P018. J. Nat. Prod.68, 1262–1265 (2005).
   PubMed Web of Science ®Google Scholar
• Lukas SM , KroeRR, WildesonJet al. Catalysis and function of the p38α-MK2a signalling complex. Biochemistry 43, 9950–9960 (2004).
   PubMed Web of Science ®Google Scholar
• Meng W , SwensonLL, FitzgibbonMJet al. Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activity with nuclear export. J. Biol. Chem. 277, 37401–37406 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson W , FregoL, PeetGWet al. Discovery and characterization of a substrate selective p38α inhibitor. Biochemistry 43, 11658–11671 (2004).
   PubMed Web of Science ®Google Scholar
• Davis T , BagleyMC, DixMCet al. Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38α MAPK inhibitors in Werner syndrome cells. Bioorg. Med. Chem. Lett. 17, 6832–6835 (2007).
   PubMedGoogle Scholar
• Almholt DLC , LoechelF, NielsenSJet al. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution® screen. Assay Drug Dev. Tech. 2, 7–20 (2004).
   PubMed Web of Science ®Google Scholar
• White A , PargellisCA, StudtsJM, WerneburgBG, FarmerBT. Molecular basis of MAPK-activated protein kinase 2: p38 assembly.Proc. Nat. Acad. Sci. USA104, 6353–6358 (2007).
   PubMed Web of Science ®Google Scholar
• ter Haar E , PrabhakarP, LiuX, LepreC. Crystal structure of the p38α–MAPKAP kinase 2 heterodimer.J. Biol. Chem.282, 9733–9739 (2007).
   PubMed Web of Science ®Google Scholar
• Underwood KW , ParrisKD, FedericoEet al. Catalytically active MAPKAP kinase 2 structures in complex with staurosporine and ADP reveals differences with the autoinhibited enzyme. Structure 11, 627–636 (2003).
   PubMed Web of Science ®Google Scholar
• Genovese MC . Inhibition of p38: has the fat lady sung?Arthritis Rheum.60, 317–320 (2009).
   PubMed Web of Science ®Google Scholar
• Gaestel M , KotlyarovA, KrachtM. Targeting innate immunity protein kinase signaling in inflammation.Nat. Rev. Drug Disc.8, 480–499 (2009)
   PubMed Web of Science ®Google Scholar

▪Patents

• Pharmacia Corporation: WO2004055015 (2004).
   Google Scholar
• Pharmacia Corporation: WO2004054505 (2004).
   Google Scholar
• Pharmacia Corporation: WO2004054504 (2004).
   Google Scholar
• Teijin Pharma Limited: WO2004081013 (2004).
   Google Scholar
• Teijin Pharma Limited: WO2004076458 (2004).
   Google Scholar
• Teijin Pharma Limited: WO2006016715 (2006).
   Google Scholar
• Teijin Pharma Limited: WO2006098519 (2006).
   Google Scholar
• Teijin Pharma Limited: WO2006109867 (2006).
   Google Scholar
• Bristol-Myers Squibb Company: WO2007038314 (2007).
   Google Scholar
• Bristol-Myers Squibb Company: US20070078136 (2007).
   Google Scholar
• Bristol-Myers Squibb Company: US20080045536 (2008).
   Google Scholar
• Galapagos N.V.: WO2007131991 (2007).
   Google Scholar
• Galapagos N.V.: WO2007138072 (2007).
   Google Scholar
• Galapagos N.V.: WO2008138842 (2008).
   Google Scholar
• Galapagos N.V.: WO2008138843 (2008).
   Google Scholar
• Pharmacia Corporation: WO2004058762 (2004).
   Google Scholar
• Pharmacia Corporation: WO2004058176 (2004).
   Google Scholar
• Novartis AG: WO2007039285 (2007).
   Google Scholar
• Novartis AG: WO2008034600 (2008).
   Google Scholar
• Novartis AG: WO2008025512 (2008).
   Google Scholar
• Novartis AG: WO2009010488 (2009).
   Google Scholar
• Pharmacia Corporation: WO2005009370 (2005).
   Google Scholar
• Boehringer Ingelheim Corporation: US2006/0276453 (2006).
   Google Scholar
• Boehringer Ingelheim Corporation: US2006/0276496 (2006).
   Google Scholar
• Boehringer Ingelheim Corporation: WO2008098096 (2008).
   Google Scholar
• Wyeth: WO2009012375 (2009).
   Google Scholar
• Astex Technology Limited: WO2005014554 (2005).
   Google Scholar
• Abbott Laboratories: WO2005110410 (2005).
   Google Scholar
• Abbott Laboratories: WO2007117465 (2007).
   Google Scholar
• GlaxoSmithKline: WO2005007092 (2005).
   Google Scholar
• Novo Nordisk A/S: WO2004099127 (2004).
   Google Scholar